TTHI, HBIO Put On Notice, Elite Gets FDA Date, VYGR Gets Ready To Sail

Voyager Therapeutics Inc.'s phase Ib clinical trial of VY-AADC01 in patients with advanced Parkinson's disease is enrolling participants. The top-line human proof-of-concept data from this data are expected in the fourth quarter of 2016.

from RTT - Biotech http://ift.tt/1Mdod0S
via IFTTT